Worsening of bruxism with atomoxetine: a case report.
Atomoxetine is the only FDA-approved non-stimulant to treat ADHD. We report a case of Atomoxetine-related exacerbation of nocturnal bruxism in a 12-yr old boy with ADHD, subsiding on discontinuing the drug, but re-worsening with retrial, finally subsiding upon adding Buspirone. This is the first report of its kind showing such an association, not included in any pre- or post-marketing data. Clinical implications and possible mechanisms are discussed.
Mendhekar
Dattatreya
D
Neuropsychiatry and Headache Clinic, Pratap Nagar, Delhi, India.
Lohia
Deep
D
D018759:Adrenergic Uptake Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D016907:Adverse Drug Reaction Reporting Systems; D000069445:Atomoxetine Hydrochloride; D001288:Attention / Q000187:drug effects; D002012:Bruxism / Q000139:chemically induced* / Q000523:psychology; D002648:Child; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D011437:Propylamines / Q000009:adverse effects* / Q000627:therapeutic use
D018759:Adrenergic Uptake Inhibitors; D011437:Propylamines; D000069445:Atomoxetine Hydrochloride